Compare CTW & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTW | ARMP |
|---|---|---|
| Founded | 2013 | N/A |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.9M | 125.7M |
| IPO Year | 2025 | N/A |
| Metric | CTW | ARMP |
|---|---|---|
| Price | $1.81 | $5.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 52.8K | ★ 55.3K |
| Earning Date | 11-17-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $90,370,793.00 | $5,054,000.00 |
| Revenue This Year | N/A | $4.48 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $29.93 | ★ N/A |
| Revenue Growth | ★ 32.07 | N/A |
| 52 Week Low | $1.71 | $0.90 |
| 52 Week High | $4.88 | $16.34 |
| Indicator | CTW | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 47.36 |
| Support Level | N/A | $5.67 |
| Resistance Level | N/A | $6.39 |
| Average True Range (ATR) | 0.00 | 0.59 |
| MACD | 0.00 | -0.12 |
| Stochastic Oscillator | 0.00 | 24.42 |
CTW Cayman operates the web-based HTML5 gaming platform G123.jp, offering free-to-play games based on Japanese animations, including Queen's Blade, So I'm a Spider, So What?, and Goblin Slayer. The platform features 29 games, with 11 in pre-registration. The Group provides a platform for game developers to generate revenue and reach an international audience through shared revenue from players' in-game purchases. It operates in Japan, Singapore, Taiwan, and China, excluding Taiwan, with the majority of revenue derived from Japan, and has one reporting segment focused on game distribution and related services.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.